Anatomy hub
Hand & Wrist: Options and What the Evidence Actually Shows
Thumb CMC osteoarthritis is the flagship small-joint regenerative query. Surgery works; nonoperative ladders matter for years before that.
Anatomy and clinical context
The thumb carpometacarpal joint is a common site of OA that limits pinch and grip. Splinting and activity changes go far.
Injections can buy time; trapeziectomy and related procedures remain durable surgical options when function collapses.
Illustration of the hand and thumb CMC joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Splinting, activity modification, hand therapy, and oral analgesics.
- Step 2
Injections
Corticosteroid and orthobiologic injectates in selected patients.
- Step 3
Surgery
Trapeziectomy ± suspensionplasty or implant arthroplasty for advanced disease.
Where cell therapy fits
Small-joint regenerative literature is limited. Frame injectates as symptom tools inside a surgical-aware care plan.
- Thumb CMC OA has a long nonoperative runway for many patients.
- Evidence for same-day cell products in CMC is sparse relative to knee OA.
- Banking is primarily a whole-body optionality play, not a CMC-specific pitch.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.